董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yat Gai Au | 男 | Chairman, Director and Chief Executive Officer | 53 | 未披露 | 1034.21 | 2025-10-31 |
| James Wai Hong Chung | 男 | Director,Chief Operating Officer and Chief Strategy Officer | 48 | 13.87万美元 | 未持股 | 2025-10-31 |
| Evana Yee Wah Hui | 女 | Independent Director | 53 | 未披露 | 未持股 | 2025-10-31 |
| Margaret Hoor Han Lo | 女 | Independent Director | 65 | 未披露 | 未持股 | 2025-10-31 |
| Wing Yan Lo | 男 | Independent Director | 64 | 未披露 | 未持股 | 2025-10-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yat Gai Au | 男 | Chairman, Director and Chief Executive Officer | 53 | 未披露 | 1034.21 | 2025-10-31 |
| James Wai Hong Chung | 男 | Director,Chief Operating Officer and Chief Strategy Officer | 48 | 13.87万美元 | 未持股 | 2025-10-31 |
| Yat Pui Au | 男 | Chief Business Officer | 51 | 未披露 | 未持股 | 2025-10-31 |
董事简历
中英对照 | 中文 | 英文- Yat Gai Au
-
Yat Gai Au是我们的首席执行官，自2014年以来一直担任我们的董事。他的职业生涯始于德意志银行（Deutsche Bank）和荷兰国际集团霸菱斯（ING Barings）的投资银行业务，是1998年至1999年赢得亚洲并购交易年度大奖的核心团队成员之一，包括价值超过40亿美元的交易。他是加州最大的房地产投资集团之一的创始合伙人。该地产集团与资产超过2500亿美元的领先养老金和私募股权基金合作。他是生物技术和科技初创公司的积极投资者。他为香港和美国的数千个贫困家庭和老人资助并参加了几场慈善活动。在新冠疫情期间，他向医院、老人和贫困家庭捐赠了超过20万个口罩。2018年9月，Au先生成立了Regencell Foundation Limited，以进一步推进他的慈善事业。Yat-gai Au先生是中医Sik-Kee Au先生的儿子。Au先生毕业于加州大学伯克利分校，获得哈斯商学院的理学学士学位。
Yat Gai Au is Chief Executive Officer and has been director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thoands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au is the son of TCM Practitioner, Mr. Sik Kee Au. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Biness. - Yat Gai Au是我们的首席执行官，自2014年以来一直担任我们的董事。他的职业生涯始于德意志银行（Deutsche Bank）和荷兰国际集团霸菱斯（ING Barings）的投资银行业务，是1998年至1999年赢得亚洲并购交易年度大奖的核心团队成员之一，包括价值超过40亿美元的交易。他是加州最大的房地产投资集团之一的创始合伙人。该地产集团与资产超过2500亿美元的领先养老金和私募股权基金合作。他是生物技术和科技初创公司的积极投资者。他为香港和美国的数千个贫困家庭和老人资助并参加了几场慈善活动。在新冠疫情期间，他向医院、老人和贫困家庭捐赠了超过20万个口罩。2018年9月，Au先生成立了Regencell Foundation Limited，以进一步推进他的慈善事业。Yat-gai Au先生是中医Sik-Kee Au先生的儿子。Au先生毕业于加州大学伯克利分校，获得哈斯商学院的理学学士学位。
- Yat Gai Au is Chief Executive Officer and has been director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thoands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au is the son of TCM Practitioner, Mr. Sik Kee Au. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Biness.
- James Wai Hong Chung
-
James Wai Hong Chung是我们的首席战略官。他自2015年7月加入Regencell Bioscience Limited担任高级副总裁。他带来了15年担任各种领导角色的经验。加入Regencell之前，他在Investment Technology Group管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他在Sungard Financial Systems工作，为银行提供前向后交易和风险管理软件解决方案。他在一家初创对冲基金IT咨询公司工作时，还获得了销售和会计管理、项目管理、技术和业务分析师等不同职位的经验。Chung的职业生涯始于担任和记黄埔环球电讯（Hutchison Global Crossing）的电信工程师，最终领导了一个小型工程师团队。Chung先生是斯坦福大学管理科学和工程系定量金融和British Columbia理工学院电信技术的毕业生。
James Wai Hong Chung has been director since December 28, 2023, Chief Operating Officer ("COO") since Augt 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015. He hass 15 years of experience in vario leading roles. Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and biness analyst when he worked at a startup hedge fund IT consulting biness. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology. - James Wai Hong Chung是我们的首席战略官。他自2015年7月加入Regencell Bioscience Limited担任高级副总裁。他带来了15年担任各种领导角色的经验。加入Regencell之前，他在Investment Technology Group管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他在Sungard Financial Systems工作，为银行提供前向后交易和风险管理软件解决方案。他在一家初创对冲基金IT咨询公司工作时，还获得了销售和会计管理、项目管理、技术和业务分析师等不同职位的经验。Chung的职业生涯始于担任和记黄埔环球电讯（Hutchison Global Crossing）的电信工程师，最终领导了一个小型工程师团队。Chung先生是斯坦福大学管理科学和工程系定量金融和British Columbia理工学院电信技术的毕业生。
- James Wai Hong Chung has been director since December 28, 2023, Chief Operating Officer ("COO") since Augt 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015. He hass 15 years of experience in vario leading roles. Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and biness analyst when he worked at a startup hedge fund IT consulting biness. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.
- Evana Yee Wah Hui
-
Evana Yee Wah Hui将在本注册声明生效后担任我们的独立董事。她拥有超过20年的零售和品牌管理经验。在The Dairy Farm Company Limited（一家领先的泛亚零售商）18年的职业生涯中，她管理着地区和地方层面的各个业务部门。她领导着健康和婴儿品类的区域开发团队，该团队遍布大中华地区和亚洲地区，覆盖9个市场，实施门店布局/陈列、品类开发和管理战略。此外，她还负责多个类别的销售和盈利能力，拥有产品创建和开发、品牌建设和客户忠诚度方面的经验。她还带头在香港推出了GNC和Boots两个品牌。在此之前，她在尼尔森公司（Nielsen）花了三年时间开发和实施市场研究，在那里她的主要客户包括联合利华、可口可乐、汇丰银行、MSD和欧莱雅。许仕仁女士参与慈善活动，例如在社区推广心理健康意识，以及在香港医院管理局合办的研讨会，以提高本地中学的自我意识和减少污名。她拥有南加州大学（University of Southern California）的MBA学位，并在米尔斯学院（Mills College）获得文学学士学位和数学荣誉学位。
Evana Yee Wah Hui has been independent director and member of audit committee, compensation committee and nominating and corporate governance committee since July 2021. She has over 20 years of retail and brand management experience. Throughout her 18 year career at the Dairy Farm Company Limited, a leading pan Asian retailer, she managed vario segments of the biness both at the regional and local level. She headed the regional category development team of the Health& Baby categories across the Greater China and Asian regions covering nine markets, implementing store layout/display, category development and management strategies. Furthermore, she was responsible for the sales and profitability of a diverse range of categories with experience in product creation and development, brand building, and ctomer loyalty. She also spearheaded the launch of both the GNC and Boots brands in Hong Kong. Prior to that, she spent three years developing and implementing market research at Nielsen, where her major clients included Unilever, Coca Cola, HSBC, MSD, and L'Oreal. Ms. Hui participated in charitable endeavors, such as promoting mental health awareness in the community and holding workshops to promote self awareness and reduce stigma in local high schools, co organized by the Hong Kong Hospital Authority. She holds an MBA from University of Southern California and graduated with a Bachelor of Arts, Mathematics (Honors) from Mills College. - Evana Yee Wah Hui将在本注册声明生效后担任我们的独立董事。她拥有超过20年的零售和品牌管理经验。在The Dairy Farm Company Limited（一家领先的泛亚零售商）18年的职业生涯中，她管理着地区和地方层面的各个业务部门。她领导着健康和婴儿品类的区域开发团队，该团队遍布大中华地区和亚洲地区，覆盖9个市场，实施门店布局/陈列、品类开发和管理战略。此外，她还负责多个类别的销售和盈利能力，拥有产品创建和开发、品牌建设和客户忠诚度方面的经验。她还带头在香港推出了GNC和Boots两个品牌。在此之前，她在尼尔森公司（Nielsen）花了三年时间开发和实施市场研究，在那里她的主要客户包括联合利华、可口可乐、汇丰银行、MSD和欧莱雅。许仕仁女士参与慈善活动，例如在社区推广心理健康意识，以及在香港医院管理局合办的研讨会，以提高本地中学的自我意识和减少污名。她拥有南加州大学（University of Southern California）的MBA学位，并在米尔斯学院（Mills College）获得文学学士学位和数学荣誉学位。
- Evana Yee Wah Hui has been independent director and member of audit committee, compensation committee and nominating and corporate governance committee since July 2021. She has over 20 years of retail and brand management experience. Throughout her 18 year career at the Dairy Farm Company Limited, a leading pan Asian retailer, she managed vario segments of the biness both at the regional and local level. She headed the regional category development team of the Health& Baby categories across the Greater China and Asian regions covering nine markets, implementing store layout/display, category development and management strategies. Furthermore, she was responsible for the sales and profitability of a diverse range of categories with experience in product creation and development, brand building, and ctomer loyalty. She also spearheaded the launch of both the GNC and Boots brands in Hong Kong. Prior to that, she spent three years developing and implementing market research at Nielsen, where her major clients included Unilever, Coca Cola, HSBC, MSD, and L'Oreal. Ms. Hui participated in charitable endeavors, such as promoting mental health awareness in the community and holding workshops to promote self awareness and reduce stigma in local high schools, co organized by the Hong Kong Hospital Authority. She holds an MBA from University of Southern California and graduated with a Bachelor of Arts, Mathematics (Honors) from Mills College.
- Margaret Hoor Han Lo
-
Margaret Hoor Han Lo自2025年6月起担任独立董事及审计委员会、薪酬委员会和提名及公司治理委员会成员。卢女士是一位经验丰富的投资者，在房地产投资领域拥有超过30年的丰富经验。她还深深投身于慈善事业，积极参与各种慈善倡议和志愿者工作。
Margaret Hoor Han Lo has been independent director and member of audit committee, compensation committee and nominating and corporate governance committee since June 2025. Ms. Lo is a seasoned investor with over 30 years of extensive experience in the real estate investments. She is also deeply committed to philanthropy, actively participating in vario charitable initiatives and volunteer work. - Margaret Hoor Han Lo自2025年6月起担任独立董事及审计委员会、薪酬委员会和提名及公司治理委员会成员。卢女士是一位经验丰富的投资者，在房地产投资领域拥有超过30年的丰富经验。她还深深投身于慈善事业，积极参与各种慈善倡议和志愿者工作。
- Margaret Hoor Han Lo has been independent director and member of audit committee, compensation committee and nominating and corporate governance committee since June 2025. Ms. Lo is a seasoned investor with over 30 years of extensive experience in the real estate investments. She is also deeply committed to philanthropy, actively participating in vario charitable initiatives and volunteer work.
- Wing Yan Lo
-
Wing Yan Lo，自2021年12月起担任脑再生科技控股有限公司独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。拥有超过三十年的生物制药、学术医学、公司治理、战略咨询经验。Lo博士毕业于剑桥大学，获得药理学哲学硕士学位和分子神经科学博士学位。Lo博士的职业生涯始于麦肯锡公司，担任管理顾问，曾在中国联通（香港）、香港电讯、花旗银行HK、I.T Limited、南华传媒集团和Kidsland International Holdings Limited担任高级职务。Lo博士目前担任多家香港联合交易所有限公司（“香港联交所”）主板上市公众公司的独立非执行董事；Lo博士是电视广播有限公司（香港联交所股份代号：511）、OCI International Holdings Limited（香港联交所股份代号：329）、CSI Properties Limited（香港联交所股份代号：497）、Jingrui Holdings Limited（香港联交所股份代号：1862）、Oshidori International Holdings Limited（香港联交所股份代号：622）的独立非执行董事。Lo博士还是南太地产公司（纽约证券交易所股票代码：NTP）的独立非执行董事，该公司以前在纽约证券交易所（“NYSE”）上市。Lo博士获委任为香港特别行政区政府太平绅士（JP），是Charles K. Kao阿尔茨海默病基金会和ISF学院的创会理事，也是Junior Achievement HK的现任主席。
Wing Yan Lo has been independent director and member of audit committee, compensation committee and nominating and corporate governance committee since December 2021. He has over three decades of biopharma, academic medicine, corporate governance, and strategic advisory experience. Dr. Lo graduated from Cambridge University with a Master of Philosophy Degree in Pharmacology and a Ph.D. Degree in Molecular Neuroscience. Dr. Lo started his career in McKinsey & Company Inc. as a management consultant and held senior positions in China Unicom, Hongkong Telecom, Citibank HK, I.T Limited, South China Media Group and Kidsland International Holdings Limited in the past. Dr. Lo currently serves as an independent non executive director of a number of public companies listed on the Main Board of The Stock Exchange of Hong Kong Limited ("HKSE"); Dr. Lo is an independent non executive director of Television Broadcasts Ltd (HKSE stock code: 511), OCI International Holdings Limited (HKSE stock code: 329), CSI Properties Limited (HKSE stock code: 497), CWT International Limited (HKSE stock code: 521) and NetDragon bSoft Holdings Limited (HKSE stock code: 777). Dr. Lo was appointed a Jtice of Peace of the Government of the Hong Kong Special Administrative Region. He holds the position of chairman and founding governor of the Charles K. Kao Foundation for Alzheimer's Disease, serves as the founding governor of ISF Academy, and is the chairman of Junior Achievement HK. - Wing Yan Lo，自2021年12月起担任脑再生科技控股有限公司独立董事及审计委员会、薪酬委员会和提名与公司治理委员会成员。拥有超过三十年的生物制药、学术医学、公司治理、战略咨询经验。Lo博士毕业于剑桥大学，获得药理学哲学硕士学位和分子神经科学博士学位。Lo博士的职业生涯始于麦肯锡公司，担任管理顾问，曾在中国联通（香港）、香港电讯、花旗银行HK、I.T Limited、南华传媒集团和Kidsland International Holdings Limited担任高级职务。Lo博士目前担任多家香港联合交易所有限公司（“香港联交所”）主板上市公众公司的独立非执行董事；Lo博士是电视广播有限公司（香港联交所股份代号：511）、OCI International Holdings Limited（香港联交所股份代号：329）、CSI Properties Limited（香港联交所股份代号：497）、Jingrui Holdings Limited（香港联交所股份代号：1862）、Oshidori International Holdings Limited（香港联交所股份代号：622）的独立非执行董事。Lo博士还是南太地产公司（纽约证券交易所股票代码：NTP）的独立非执行董事，该公司以前在纽约证券交易所（“NYSE”）上市。Lo博士获委任为香港特别行政区政府太平绅士（JP），是Charles K. Kao阿尔茨海默病基金会和ISF学院的创会理事，也是Junior Achievement HK的现任主席。
- Wing Yan Lo has been independent director and member of audit committee, compensation committee and nominating and corporate governance committee since December 2021. He has over three decades of biopharma, academic medicine, corporate governance, and strategic advisory experience. Dr. Lo graduated from Cambridge University with a Master of Philosophy Degree in Pharmacology and a Ph.D. Degree in Molecular Neuroscience. Dr. Lo started his career in McKinsey & Company Inc. as a management consultant and held senior positions in China Unicom, Hongkong Telecom, Citibank HK, I.T Limited, South China Media Group and Kidsland International Holdings Limited in the past. Dr. Lo currently serves as an independent non executive director of a number of public companies listed on the Main Board of The Stock Exchange of Hong Kong Limited ("HKSE"); Dr. Lo is an independent non executive director of Television Broadcasts Ltd (HKSE stock code: 511), OCI International Holdings Limited (HKSE stock code: 329), CSI Properties Limited (HKSE stock code: 497), CWT International Limited (HKSE stock code: 521) and NetDragon bSoft Holdings Limited (HKSE stock code: 777). Dr. Lo was appointed a Jtice of Peace of the Government of the Hong Kong Special Administrative Region. He holds the position of chairman and founding governor of the Charles K. Kao Foundation for Alzheimer's Disease, serves as the founding governor of ISF Academy, and is the chairman of Junior Achievement HK.
高管简历
中英对照 | 中文 | 英文- Yat Gai Au
Yat Gai Au是我们的首席执行官，自2014年以来一直担任我们的董事。他的职业生涯始于德意志银行（Deutsche Bank）和荷兰国际集团霸菱斯（ING Barings）的投资银行业务，是1998年至1999年赢得亚洲并购交易年度大奖的核心团队成员之一，包括价值超过40亿美元的交易。他是加州最大的房地产投资集团之一的创始合伙人。该地产集团与资产超过2500亿美元的领先养老金和私募股权基金合作。他是生物技术和科技初创公司的积极投资者。他为香港和美国的数千个贫困家庭和老人资助并参加了几场慈善活动。在新冠疫情期间，他向医院、老人和贫困家庭捐赠了超过20万个口罩。2018年9月，Au先生成立了Regencell Foundation Limited，以进一步推进他的慈善事业。Yat-gai Au先生是中医Sik-Kee Au先生的儿子。Au先生毕业于加州大学伯克利分校，获得哈斯商学院的理学学士学位。
Yat Gai Au is Chief Executive Officer and has been director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thoands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au is the son of TCM Practitioner, Mr. Sik Kee Au. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Biness.- Yat Gai Au是我们的首席执行官，自2014年以来一直担任我们的董事。他的职业生涯始于德意志银行（Deutsche Bank）和荷兰国际集团霸菱斯（ING Barings）的投资银行业务，是1998年至1999年赢得亚洲并购交易年度大奖的核心团队成员之一，包括价值超过40亿美元的交易。他是加州最大的房地产投资集团之一的创始合伙人。该地产集团与资产超过2500亿美元的领先养老金和私募股权基金合作。他是生物技术和科技初创公司的积极投资者。他为香港和美国的数千个贫困家庭和老人资助并参加了几场慈善活动。在新冠疫情期间，他向医院、老人和贫困家庭捐赠了超过20万个口罩。2018年9月，Au先生成立了Regencell Foundation Limited，以进一步推进他的慈善事业。Yat-gai Au先生是中医Sik-Kee Au先生的儿子。Au先生毕业于加州大学伯克利分校，获得哈斯商学院的理学学士学位。
- Yat Gai Au is Chief Executive Officer and has been director since 2014. He began his career in investment banking at Deutsche Bank and ING Barings and was one of the core team members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over $4 billion worth of deals. He is an active property, technology and biotech investor. He funds and participates in several charity events for thoands of underprivileged families and elderlies in Hong Kong and the U.S. During the COVID 19 outbreak, he donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au set up Regencell Foundation Limited to further his charitable endeavors. Mr. Au is the son of TCM Practitioner, Mr. Sik Kee Au. Mr. Au graduated from University of California, Berkeley with a Bachelor of Science degree from the Haas School of Biness.
- James Wai Hong Chung
James Wai Hong Chung是我们的首席战略官。他自2015年7月加入Regencell Bioscience Limited担任高级副总裁。他带来了15年担任各种领导角色的经验。加入Regencell之前，他在Investment Technology Group管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他在Sungard Financial Systems工作，为银行提供前向后交易和风险管理软件解决方案。他在一家初创对冲基金IT咨询公司工作时，还获得了销售和会计管理、项目管理、技术和业务分析师等不同职位的经验。Chung的职业生涯始于担任和记黄埔环球电讯（Hutchison Global Crossing）的电信工程师，最终领导了一个小型工程师团队。Chung先生是斯坦福大学管理科学和工程系定量金融和British Columbia理工学院电信技术的毕业生。
James Wai Hong Chung has been director since December 28, 2023, Chief Operating Officer ("COO") since Augt 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015. He hass 15 years of experience in vario leading roles. Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and biness analyst when he worked at a startup hedge fund IT consulting biness. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.- James Wai Hong Chung是我们的首席战略官。他自2015年7月加入Regencell Bioscience Limited担任高级副总裁。他带来了15年担任各种领导角色的经验。加入Regencell之前，他在Investment Technology Group管理亚洲股票和衍生品电子交易平台，在那里他获得了丰富的银行和金融经验。在此之前，他在Sungard Financial Systems工作，为银行提供前向后交易和风险管理软件解决方案。他在一家初创对冲基金IT咨询公司工作时，还获得了销售和会计管理、项目管理、技术和业务分析师等不同职位的经验。Chung的职业生涯始于担任和记黄埔环球电讯（Hutchison Global Crossing）的电信工程师，最终领导了一个小型工程师团队。Chung先生是斯坦福大学管理科学和工程系定量金融和British Columbia理工学院电信技术的毕业生。
- James Wai Hong Chung has been director since December 28, 2023, Chief Operating Officer ("COO") since Augt 2021 and Chief Strategy Officer since October 2020. He has joined Regencell Bioscience Limited as senior vice president since July 2015. He hass 15 years of experience in vario leading roles. Prior to joining Regencell, Mr. Chung managed the Asia equities and derivatives electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for banks. He also gained experiences in different roles from sales and accounting management, project management, technology and biness analyst when he worked at a startup hedge fund IT consulting biness. Mr. Chung started his career as a telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications Technology from British Columbia Institute of Technology.
- Yat Pui Au
Yat Pui Au，自2023年2月起担任脑再生科技控股有限公司首席商务官。他自2021年10月起加入脑再生科技有限公司，担任高级副总裁。他在战略管理和业务运营方面拥有超过24年的经验。在加入Regencell之前，他曾在实体安全和财产管理部门担任多个领导职务，在那里他实施了数字化和基于云的CRM解决方案，完成了政府/机构/私营部门的重大技术项目，并简化了营销、财务、IT、人力资源和运营部门的业务运营。Au先生的职业生涯始于美国计算机科学公司的IT/MIS集成和部署顾问分析师。区先生在加州大学伯克利分校获得法律研究学士学位。
Yat Pui Au has been Chief Biness Officer ("CBO") since February 2023. He has joined Regencell Bioscience Limited as senior vice president since October 2021. He has more than 24 years of experience in strategic management and biness operations. Prior to joining Regencell, he worked at vario leading roles in the physical security and property management sectors, where he implemented digital and cloud based Ctomer Relationship Management solutions, completed major technology projects for governmental/institutional/private sectors, and streamlined biness operations across marketing, finance, IT, HR and operations departments. Mr. Yat Pui Au started his career as a consultant analyst for Computer Sciences Corporation for IT/MIS integrations and deployment.He obtained his Bachelor's degree in Legal Studies from UC Berkeley.- Yat Pui Au，自2023年2月起担任脑再生科技控股有限公司首席商务官。他自2021年10月起加入脑再生科技有限公司，担任高级副总裁。他在战略管理和业务运营方面拥有超过24年的经验。在加入Regencell之前，他曾在实体安全和财产管理部门担任多个领导职务，在那里他实施了数字化和基于云的CRM解决方案，完成了政府/机构/私营部门的重大技术项目，并简化了营销、财务、IT、人力资源和运营部门的业务运营。Au先生的职业生涯始于美国计算机科学公司的IT/MIS集成和部署顾问分析师。区先生在加州大学伯克利分校获得法律研究学士学位。
- Yat Pui Au has been Chief Biness Officer ("CBO") since February 2023. He has joined Regencell Bioscience Limited as senior vice president since October 2021. He has more than 24 years of experience in strategic management and biness operations. Prior to joining Regencell, he worked at vario leading roles in the physical security and property management sectors, where he implemented digital and cloud based Ctomer Relationship Management solutions, completed major technology projects for governmental/institutional/private sectors, and streamlined biness operations across marketing, finance, IT, HR and operations departments. Mr. Yat Pui Au started his career as a consultant analyst for Computer Sciences Corporation for IT/MIS integrations and deployment.He obtained his Bachelor's degree in Legal Studies from UC Berkeley.